This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
41
Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Clinical cure rate
Time frame: 21-24 days after start of study treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research site
Chicago, Illinois, United States
Research site
Springfield, Missouri, United States
Research site
Greensboro, North Carolina, United States
Research Site 1
Belo Horizonte, Brazil
Research Site 2
Belo Horizonte, Brazil
Research Site
Itaquaquecetuba, Brazil
Research Site
Porto Alegre, Brazil
Research Site
São José do Rio Preto, Brazil
Research site 1
Zagreb, Croatia
Research site 2
Zagreb, Croatia
...and 51 more locations